EuBIVAS项目:酶法和碱性苦味酸法检测血清肌酐的个体内与个体间生物学变异数据及其监测意义
EuBIVAS项目在91名健康个体中连续10周采血,用酶法和碱性苦味酸法测定血清肌酐生物学变异。酶法与碱性苦味酸法的个体内变异(CVI)分别为4.4%和4.7%,均低于现有在线估计值5.9%;碱性苦味酸法分析变异(CVA)为4.4%,未能满足分析性能规范。
要点
- 酶法与碱性苦味酸法获得的血清肌酐CVI相似,均低于现有在线数据。
- 碱性苦味酸法CVA为4.4%,未达到基于CVI推导的分析性能规范。
- 未发现性别间生物学变异差异,但男女间及国籍间肌酐均值存在显著差异。
核心结论
- EuBIVAS获得的血清肌酐CVI比既往数据更严格,据此推导的CVAPS更严格;碱性苦味酸法未能满足该CVAPS,其未来应用存疑。
研究设计与样本
- EuBIVAS多中心研究,纳入91名健康个体(38男,53女,年龄21-69岁),连续10周在6个欧洲实验室采血,血清存于-80°C后统一检测。
主要发现
- 酶法CVI(95%CI)为4.4%(4.2-4.7),碱性苦味酸法为4.7%(4.4-4.9),均低于现有在线CVI估计值5.9%。
- 酶法CVA为1.1%,碱性苦味酸法CVA为4.4%。
- 男女间及土耳其裔与其他国籍个体间肌酐均值存在显著差异,但未发现性别间BV差异。
- 按分层计算的个体间BV(CVG)与历史BV数据相似。
关键数值与推荐
- 酶法CVI为4.4%(95%CI 4.2-4.7),碱性苦味酸法CVI为4.7%(95%CI 4.4-4.9)。
- 酶法CVA为1.1%,碱性苦味酸法CVA为4.4%,后者未满足基于CVI的CVAPS。
临床怎么用
- 实验室应优先采用酶法检测血清肌酐以满足更严格的CVAPS,碱性苦味酸法因CVA不达标不宜继续使用。
- 解读血清肌酐变化时应参考EuBIVAS提供的更严格CVI数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The European Federation of Clinical Chemistry and Laboratory Medicine (EFLM) European Biological Variation Study (EuBIVAS) has been established to deliver rigorously determined biological variation (BV) indices. EuBIVAS determined BV for serum creatinine using the enzymatic and alkaline picrate measurement methods. METHOD: In total, 91 healthy individuals (38 males, 53 females; age range, 21-69 years) were bled for 10 consecutive weeks at 6 European laboratories. An equivalent protocol was followed at each center. Sera were stored at -80 °C before analysis. Analyses for each patient were performed in duplicate within a single run on an ADVIA 2400 system (San Raffaele Hospital, Milan). The data were subjected to outlier and homogeneity analysis before performing CV-ANOVA to determine BV and analytical variation (CVA) estimates with confidence intervals (CI). RESULTS: The within-subject BV estimates [CVI (95% CI)] were similar for enzymatic [4.4% (4.2-4.7)] and alkaline picrate [4.7% (4.4-4.9)] methods and lower than the estimate presently available online (CVI = 5.9%). No significant male/female BV differences were found. Significant differences were observed in mean creatinine values between men and women and between Turkish individuals and those of other nationalities. Between-subject BV (CVG) estimates, stratified accordingly, produced CVG values similar to historical BV data. CVA was 1.1% for the enzymatic and 4.4% for alkaline picrate methods, indicating that alkaline picrate methods fail to fulfill analytical performance specifications for imprecision (CVAPS). CONCLUSIONS: The serum creatinine CVI obtained by EuBIVAS specifies a more stringent CVAPS than previously identified. The alkaline picrate method failed to meet this CVAPS, raising questions regarding its future use.
引用
- Carobene A, Marino I, Coşkun A, et al. The EuBIVAS Project: Within- and Between-Subject Biological Variation Data for Serum Creatinine Using Enzymatic and Alkaline Picrate Methods and Implications for Monitoring. Clin Chem. 2017. PMID: 28720681. doi:10.1373/clinchem.2017.275115
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。